 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Being a big fan of startup companies or companies revamping their business, I found this little gem and have fallen in love with it. Being significantly undervalued (around $8, and warrants at an even better deal) this company was too good to pass up. Here's a sample of the kind of developments to expect over the next year or two: ( BW)(MEDJET)(MDJT) Medjet Announces Completion of HydroBrush Prototype Business Editors and Medical/Health Writers EDISON, N.J.--(BUSINESS WIRE)--Feb. 6, 1997--Medjet, Inc. (NASDAQ: MDJT common; MDJTW warrants), a leading developer of surgical cutting devices based on high-velocity water jets, today announced the completion of the prototype for its HydroBrush(TM) Keratome for removing (debriding) epithelium from the cornea over a defined area. The HydroBrush(TM) is a small hand tool with a transparent applanating surface that is placed against the area to be debrided. A circular jet of water operated at a pressure of about 4,000 psi acts as the brush. The surgeon moves the tool across the cornea to produce a perfect circular debridement, typically 7-8 millimeters in diameter, in approximately two seconds. Removal of the epithelium is the first step in excimer laser refractive surgery, known as PRK. It is also used for treating various corneal problems associated with disease, infection, dystrophy and physical damage to the epithelium. Eugene I. Gordon, president and chief executive officer, commented, "Until now, removal of the epithelium has been accomplished by scraping the surface of the cornea with a metal blade, a relatively slow procedure that often damages the underlying Bowman's layer and generally leaves debris on the surface. There is a growing belief in the ophthalmic community that the several minutes required to perform the epithelial removal and the associated uncontrolled hydration of the cornea contribute in part to the inaccuracy of PRK in regularly achieving the intended refractive correction. If this proves to be the case, then the new epithelial removal device, because of its speed, could be extremely important. "The HydroBrush(TM) epithelial debridement, in contract, is done quickly, produces an immaculate surface totally free of debris and, based on Medjet's studies to date on cadaver eyes, causes no damage to the Bowman's layer. Based on the company's trials to date using live rabbits, the debrided epithelium heals at least as well as with a knife blade removal and typically more quickly." The prototype of the company's other early product, the HydroBlade(TM) Keratome for therapeutic lamellar keratoplasty, is expected to be available for clinical testing by the end of the first quarter of 1997. Medjet Inc.'s HydroBlade(TM) and HydroBrush(TM) Keratomes are proprietary surgical devices that utilize a hair-thin circular beam of supersonic-velocity water to cut layers of the cornea and other human tissue. In lamellar keratoplasty, based on initial experiments on enucleated eyes and live rabbit eyes, the company's HydroBlade(TM) Keratome is expected to be safer, more accurate and less expensive than other scalpel-based cutting devices and to result in a more stable corneal adjustment that is less painful for patients. All statements regarding the anticipated or expected benefits of the HydroBrush(TM) Keratome and the HydroBlade(TM) Keratome and the timetable for delivery of the HydroBlade(TM) Keratome and the application to the FDA are merely projections and may not be realized. --30--rc/ny* CONTACT: Medjet Inc. Eugene I. Gordon, 908/738-3990 or Lobsenz Stevens, Inc. Mark Perlgut, 212/684-6300 ext. 309 KEYWORD: NEW JERSEY INDUSTRY KEYWORD: MEDICINE BIOTECHNOLOGY PRODUCT REPEATS: New York 212-752-9600 or 800-221-2462; Boston 617-236-4266 or 800-225-2030; SF 415-986-4422 or 800-227-0845; LA 310-820-9473 Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com Any thoughts......... | ||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |